公开(公告)号：EP4173639A1

公开(公告)日：2023-05-03

申请号：EP21830069.7

申请日：2021-06-28

申请人： RaQualia Pharma Inc.

发明人： IIDA Tadashi ,  ENOMOTO Atsushi ,  MIZUTANI Yasuyuki ,  TAKAHASHI Masahide ,  FUJISHIRO Mitsuhiro ,  KAWASHIMA Hiroki ,  MATSUKAWA Yoshihisa ,  OWAKI Takayuki

IPC分类号： A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  A61P43/00 ,  A61K47/64 ,  C12N15/86 ,  C12Q1/6841 ,  G01N33/48 ,  G01N33/574 ,  A61K35/76 ,  A61K31/192 ,  A61K31/337 ,  A61K31/7068

摘要： The present invention provides a method for selecting a cancer patient for whom a combination therapy with a retinoid and a cancer treatment agent is effective, which comprises a step of selecting a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma. In addition, the present invention provides a medicament which comprises a cancer patient having a malignant tumor with the infiltration of cancer-associated fibroblasts in the stroma is a subject and is administered in combination of a retinoid and a cancer therapeutic agent.

公开(公告)号：EP3774739A1

公开(公告)日：2021-02-17

申请号：EP19785626.3

申请日：2019-04-09

申请人： RaQualia Pharma Inc. ,  National University Corporation Tokai National Higher Education and Research System

发明人： OHMI, Masashi ,  MATSUSHITA, Takeshi ,  ANDO, Kazuo ,  YAMAGUCHI, Ryuichi ,  FUKUMOTO, Yutaka ,  MAGARA, Ryohei ,  YAMAGISHI, Tatsuya ,  TAKEFUJI, Mikito

IPC分类号： C07D235/26 ,  A61K31/4184 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/5383 ,  A61P1/00 ,  A61P9/00 ,  A61P25/00 ,  A61P29/00 ,  A61P43/00 ,  C07D401/12

公开(公告)号：EP3116858B1

公开(公告)日：2020-11-11

申请号：EP15760744.1

申请日：2015-03-16

申请人： RaQualia Pharma Inc.

发明人： SHISHIDO, Yuji ,  OHMI, Masashi ,  ANDO, Kazuo

IPC分类号： C07D235/02 ,  A61K31/506 ,  A61K31/501 ,  A61K31/4985 ,  A61K31/498 ,  A61K31/497 ,  A61K31/4709 ,  A61K31/4439 ,  A61K31/4375 ,  A61K31/437 ,  A61K31/427 ,  A61K31/421 ,  A61K31/4166 ,  A61K31/4164 ,  A61K31/41 ,  A61P13/02 ,  A61P11/00 ,  A61P1/00 ,  A61P9/10

公开(公告)号：EP3632899A1

公开(公告)日：2020-04-08

申请号：EP19210864.5

申请日：2010-05-31

申请人： RaQualia Pharma Inc.

发明人： INOUE, Tadashi ,  WATANABE, Shuzo ,  YAMAGISHI, Tatsuya ,  ARANO, Yoshimasa ,  MORITA, Mikio ,  SHIMADA, Kaoru

IPC分类号： C07D213/65 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/506 ,  A61P1/00 ,  A61P1/18 ,  A61P9/00 ,  A61P9/06 ,  A61P13/00 ,  A61P13/10 ,  A61P15/00 ,  A61P19/02 ,  A61P21/02

摘要： The present invention relates to aryl substituted carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof, which have blocking activities of T-type calcium channels or voltage gated sodium channels as the tetrodotoxin-sensitive (TTX-S) blockers such as Na V1.3 and Na V1.7 , and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels or voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels or voltage gated sodium channels are involved.

公开(公告)号：EP2435407B1

公开(公告)日：2019-12-25

申请号：EP10780311.6

申请日：2010-05-31

申请人： RaQualia Pharma Inc.

发明人： INOUE, Tadashi ,  WATANABE, Shuzo ,  YAMAGISHI, Tatsuya ,  ARANO, Yoshimasa ,  MORITA, Mikio ,  SHIMADA, Kaoru

IPC分类号： C07D213/65 ,  A61K31/44 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/506 ,  A61P1/00 ,  A61P1/18 ,  A61P9/00 ,  A61P9/06 ,  A61P13/00 ,  A61P13/10 ,  A61P15/00 ,  A61P19/02 ,  A61P21/02

公开(公告)号：EP3145926A4

公开(公告)日：2017-12-27

申请号：EP15796887

申请日：2015-05-20

申请人： RAQUALIA PHARMA INC

发明人： NUMATA TOYOHARU ,  SUDO MASAKI ,  SUN XUFENG

IPC分类号： C07D413/14 ,  A61K31/454 ,  A61P1/04 ,  A61P1/10 ,  A61P1/14 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P11/16 ,  A61P25/00 ,  A61P25/06 ,  A61P25/28 ,  A61P43/00

CPC分类号： C07D413/14 ,  A61K31/454

摘要： Salts of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}tetrahydro-2H-pyran-4-carboxylic acid are disclosed. More particularly, salt forms (HCl-salt, HBr-salt, p-toluenesulfonate salt and ethanedisulfonate salt) are disclosed. Furthermore, processes for the preparation of such salt forms, compositions containing such salt forms, and uses of such salt forms are disclosed. A method of treating disease conditions mediated by 5-HT4 receptor activity includes administering an effective amount of such salt forms to an animal, including a human, in need of such treatment.

公开(公告)号：EP2922849B1

公开(公告)日：2017-07-12

申请号：EP13856306.9

申请日：2013-11-21

申请人： RaQualia Pharma Inc.

发明人： NUMATA, Toyoharu ,  AOYAMA, Hideyuki ,  MURAJI, Kaori

IPC分类号： C07D413/14 ,  A61K31/454 ,  A61P1/04 ,  A61P1/10 ,  A61P1/14 ,  A61P3/10 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P11/16 ,  A61P25/00 ,  A61P25/04 ,  A61P25/06 ,  A61P25/28 ,  A61P43/00

CPC分类号： C07D413/14 ,  C07B2200/13

公开(公告)号：EP2422779B1

公开(公告)日：2016-01-06

申请号：EP10767106.7

申请日：2010-04-22

申请人： RaQualia Pharma Inc.

发明人： TAKE, Yukinori ,  KOIZUMI, Shinichi ,  OKUMURA, Takako ,  NONOMURA, Kazuhiko

IPC分类号： A61K31/192 ,  A61K31/437 ,  A61K31/4412 ,  A61P35/00 ,  A61P43/00 ,  C07D213/64 ,  C07D471/04

CPC分类号： C07D471/04 ,  A61K31/192 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4412 ,  A61K45/06 ,  C07C235/60 ,  C07D213/82

摘要： This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

公开(公告)号：EP2854810A1

公开(公告)日：2015-04-08

申请号：EP13793644.9

申请日：2013-05-27

申请人： RaQualia Pharma Inc

发明人： TAKAHASHI, Nobuyuki ,  SUDO, Masaki ,  SHIMADA, Kaoru ,  WAKABAYASHI, Hiroaki

IPC分类号： A61K31/5025 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/4162 ,  A61K31/435 ,  A61K31/454 ,  A61K31/55 ,  A61K38/00 ,  A61P1/04 ,  A61P1/14

CPC分类号： A61K38/12 ,  A61K31/395 ,  A61K31/40 ,  A61K31/4045 ,  A61K31/4164 ,  A61K31/437 ,  A61K31/444 ,  A61K31/445 ,  A61K31/45 ,  A61K31/454 ,  A61K31/5025 ,  A61K38/26 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention relates to a use of a compound having ghrelin receptor agonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for treatment of diseases including achlorhydria in which abnormal gastric acid secretion is involved. In addition, the present invention relates to the method of treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agents. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound of the present invention or a pharmaceutically acceptable salt thereof for the treatment of said diseases.

公开(公告)号：EP2841421A1

公开(公告)日：2015-03-04

申请号：EP13781524.7

申请日：2013-04-25

申请人： RaQualia Pharma Inc

发明人： YAMAGISHI, Tatsuya ,  KAWAMURA, Kiyoshi ,  MORITA, Mikio

IPC分类号： C07D213/75 ,  A61K31/44 ,  A61K31/4523 ,  A61K31/455 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61P1/00 ,  A61P25/18 ,  A61P25/28 ,  A61P29/00 ,  A61P43/00 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12

CPC分类号： C07D401/12 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D213/75 ,  C07D213/81 ,  C07D213/82 ,  C07D401/04

摘要： The present invention relates to amide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which voltage gated sodium channels are involved.

摘要翻译： 本发明涉及具有电压门控钠通道作为TTX-S通道的阻断活性的酰胺衍生物，其可用于治疗或预防涉及电压门控钠通道的疾病和疾病。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病中的用途。